ALNYLAM PHARMACEUTICALS, INC. - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2006. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics based on RNA interference (RNAi). The company has not yet received regulatory approval for any products and has incurred significant losses since its inception in 2002. As of June 30, 2006, the company had an accumulated deficit of $124.7 million.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2006 | Six Months Ended June 30, 2006 |
|---|---|---|
| Net Revenues | $6.0 million | $11.7 million |
| Net Loss | $(9.9) million | $(18.8) million |
| Net Loss Per Share (Basic & Diluted) | $(0.31) | $(0.60) |
| Cash and Cash Equivalents | $35.6 million (Balance Sheet) | N/A |
| Total Cash, Equivalents & Marketable Securities | $123.3 million (Balance Sheet) | N/A |
| Notes Payable (Total) | $9.1 million (Outstanding) | N/A |
| Net Cash Used in Operating Activities | N/A | $(17.1) million |
Note: The company reported no product sales revenue; revenues are derived primarily from strategic alliances and license fees.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased significantly to $6.0 million for the three months ended June 30, 2006, compared to $1.1 million in the same period in 2005. This was driven primarily by the Novartis collaboration agreements, which generated $5.6 million in revenue for the quarter.
- Expense Increases: Total operating expenses rose to $17.1 million (Q2 2006) from $12.3 million (Q2 2005). Research and Development (R&D) expenses increased by 38% to $12.7 million, largely due to clinical trial and manufacturing costs for the RSV program and the adoption of SFAS 123R (stock-based compensation).
- Stock-Based Compensation: The adoption of SFAS 123R on January 1, 2006, resulted in a significant increase in non-cash stock-based compensation expense, totaling $4.0 million for the six months ended June 30, 2006, compared to $1.4 million in the prior year period.
- Liquidity: Cash and cash equivalents increased from $15.8 million at December 31, 2005, to $35.6 million at June 30, 2006, bolstered by a $62.2 million follow-on public offering in January 2006.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring significant losses over the next several years as R&D activities expand. The company believes its current resources, combined with expected cash from alliances, will fund operations beyond the end of 2007.
- Clinical Progress: The company initiated Phase I clinical trials for ALN-RSV01 (RSV treatment) in December 2005, with results released in May 2006 showing the drug was safe and well-tolerated. A Phase II trial is planned for the first half of 2007.
- Collaborations:
- Novartis: A broad alliance and a specific pandemic flu alliance are key revenue drivers. Novartis holds approximately 19.9% of the company's stock.
- Merck: On July 3, 2006, the company amended its collaboration agreement with Merck to focus on nine additional targets and terminated a separate ocular collaboration agreement.
- Risks:
- Technology Risk: RNAi is an unproven technology; no company has yet received regulatory approval for an RNAi therapeutic.
- Capital Needs: The company will require substantial additional funds to complete R&D and clinical trials. Failure to secure funding could force a curtailment of operations.
- Dependence on Partners: The business relies heavily on collaborations with Novartis and Merck for funding and commercialization capabilities.
- Patent Litigation: The RNAi field is subject to significant patent uncertainty and potential litigation.
Key Facts for Investor Verification
- Revenue Source: Verify the sustainability of revenue streams, which are currently almost entirely dependent on upfront payments and milestones from Novartis and Merck, rather than product sales.
- Cash Burn Rate: Monitor the net cash used in operating activities ($17.1 million for six months) against the cash balance ($123.3 million including marketable securities) to assess runway.
- Accounting Changes: Note the impact of SFAS 123R adoption on reported net loss, which increased expenses by approximately $2.9 million for the six-month period.
- Debt Obligations: Review the terms of the equipment lines of credit with Oxford Finance and Lighthouse Capital, totaling approximately $9.1 million outstanding as of June 30, 2006.
- Merck Agreement: Confirm the details of the July 3, 2006, amended agreement with Merck and the termination of the ocular collaboration, as these affect future revenue recognition and deferred revenue balances.